Menu
No results found.
Weekly Share Price & Valuation Overview
Zhejiang Orient Gene Biotech Co., Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. The company offers IFA solutions, digital test, oral fluid test, and covid-19 test products; and immunological diagnosis product, such as hair drug test kit, monkeypox, saliva drug test, urine multi-drug test, urine single-drug test, rapid test, digital pregnancy test, male-fertility test, menopause test, and other test products. It also provides molecular diagnosis products, including nucleic acid extraction systems, real time PCR systems, virus detection kits, viral nucleic acid extraction kits, and general products; liquid biochip products; mini immunofluorescence analyzers, handheld fluorescence immunoassay analyzers, fluorescence immunoassay analyzers, handheld oral fluid drug test readers, colloidal gold test readers, and urine drug test cup readers; and dry biochemical strips comprising urine reagent strips, urine analyzers, alcohol test, and vaginal pH test products. In addition, the company offers raw materials for fertility, tumor and cardiac marker, drugs of abuse, infectious diseases, pet, antibody, and others; and FISH probes comprising solid tumor probes, chromosome test, hematologic disease probes, reagents, and instruments. Zhejiang Orient Gene Biotech Co., Ltd was founded in 2005 and is based in Huzhou, China.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 5.70B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 3.04B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 836.95M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 162.00M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY -580.82M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 4.26
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -2.93
- Shares Outstanding
- 201.60M
- Float Shares
- 95.30M
- Implied Shares Outstanding
- 201.88M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-76.23%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-69.40%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
19.36%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-68.96%
- ROA Return on assets: net income ÷ total assets.
-
-5.80%
- ROE Return on equity: net income ÷ shareholder equity.
-
-8.73%
- Revenue Growth Year-over-year revenue growth.
-
4.90%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 3.54
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.05
- Total Cash Cash and equivalents.
- CNY 2.93B
- Total Debt Short + long-term interest-bearing debt.
- CNY 363.94M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CNY -2.57B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -0.63
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY -190.75M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY -890.36M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-22.79%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-106.38%
- Cash Conversion (OpCF/EBITDA)
- 0.33
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.